Question:
What is the 2019 average sales price (ASP) rate for nonpass-through drugs and biologicals?
Answer:
For 2019, payment for nonpass-through drugs and biologicals that were not acquired through the 340B Program is made at a single rate of ASP + 6 percent (or ASP – 22.5 percent if acquired under the 340B Program), which provides payment for both the acquisition cost and pharmacy overhead costs associated with the drug or biological.
This information can be found at https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2019Downloads/R4255CP.pdf
